FDA accepts Dato-DXd BLA for breast cancer
2 April 2024
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast…
71,500€
-0,35%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance
AstraZenecas (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.…
AstraZenecas (AZN) Rare Blood Disorder Drug Gets FDA Nod
FDA approves AstraZenecas (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult…
AstraZeneca gets FDA approval for PNH drug Voydeya
…
DEUTSCHE BANK RESEARCH stuft ASTRAZENECA auf Sell
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca auf "Sell" mit einem Kursziel von 9500 Pence…